Forge Biologics
Date | Investors | Amount | Round |
---|---|---|---|
- |
| N/A | - |
N/A | Spinout | ||
$40.0m | Series A | ||
$120m | Series B | ||
* | $90.0m Valuation: $600m | Series C | |
* | $620m Valuation: $620m | Acquisition | |
* | N/A | Growth Equity VC | |
Total Funding | €227m |
Recent News about Forge Biologics
EditForge Biologics is a biotechnology startup that specializes in the development and manufacturing of gene therapies. The company operates in the rapidly expanding gene therapy market, serving clients ranging from preclinical stage to commercial manufacturing. Their primary focus is on advancing gene therapy programs that aim to treat patients suffering from rare and devastating diseases.
The company's business model is centered around its proprietary "gene therapy development engine." This engine allows Forge Biologics to take innovative gene therapy concepts and bring them to reality, providing end-to-end manufacturing services. This means they handle everything from the initial development stages to the final production of the gene therapies.
Forge Biologics operates out of a custom-designed, 200,000+ square foot cGMP (Current Good Manufacturing Practice) facility, known as the Hearth. This facility allows them to manufacture AAV (Adeno-Associated Virus) gene therapies, a type of gene therapy that uses a virus to deliver genes into cells.
The company generates revenue by providing these manufacturing services to other companies and researchers in the gene therapy field. Additionally, they also develop their own innovative gene therapies, which could potentially provide additional revenue streams if these therapies are approved and commercialized.
In summary, Forge Biologics is a trailblazer in the gene therapy field, providing comprehensive manufacturing services and developing innovative therapies to treat genetic diseases.
Keywords: Gene Therapy, Biotechnology, Manufacturing, AAV Gene Therapies, Rare Diseases, Preclinical Stage, Commercial Manufacturing, cGMP Facility, Hearth, Genetic Diseases.